More than 10 clinical trials of A␤ immunotherapy are currently underway in patients with Alzheimer's disease (AD). The aim is to identify safe approaches for the efficacious antibody-mediated removal of brain ␤-amyloid or its neurotoxic oligomeric precursors consisting of aggregated amyloid ␤-peptide (A␤). Initial experimental and neuro-pathological evidence for clearance of brain ␤-amyloid in response to A␤ immunotherapy is associated with structural and functional rescue of neurons, as well as initial signs of clinical stabilization and reduced rates of dementia progression. For the next steps in the future improvement of A␤ immunotherapy, major challenges in pharmacokinetics, safety, and tolerability need to be addressed. These include the low penetrations rates of IgG molecules through the blood-brain barrier, possible reductions in brain volume, the possibility of autoimmune disease related to unwanted crossreactivity with endogenous antigens on physiological structures, micro-hemorrhages related to cross-reaction with preexisting vascular amyloid pathology, possible relocalization of A␤ from ␤-amyloid plaques to brain blood vessels resulting in increased amyloid angiopathy, and the lacking activity of A␤ antibodies on pre-existing neurofibrillary tangle pathology, as well as the lacking molecular identification of the forms of A␤ to be therapeutically targeted. The solutions to these problems will be guided by the fine lines between tolerance and immunity against physiological and pathological structures, respectively, as well as by the understanding of the pathogenic transition of soluble A␤ into toxic oligomeric aggregation intermediates in the dynamic equilibrium of ␤-amyloid fibril assembly. Provided that the ongoing and planned clinical trials address these issues in a timely manner, there is a good chance for A␤ immunotherapy to be one of the first disease-modifying therapies of Alzheimer's disease to be introduced into clinical practice. Key Words: Humanized monoclonal antibody, neurodegeneration, vaccination, clinical trial, APP, passive immunization.
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PROOF OF CONCEPT IN EXPERIMENTAL ANIMALS
The concept of A␤ immunotherapy was first introduced by Schenk et al. 1 who showed that vaccination with A␤1-42 and Freund's adjuvant prevented ␤-amyloid formation in brains of young transgenic mice and removed ␤-amyloid in older mice with pre-existing pathology. Subsequent active vaccinations in transgenic mice, nonhuman primates, and other species confirmed these findings [2] [3] [4] [5] [6] (For review, see references [7] [8] [9] [10] ). Moreover, the passive transfer of antibodies against A␤ can efficiently reduce ␤-amyloid pathology. [11] [12] [13] [14] [15] [16] [17] [18] [19] The immunotherapy-mediated clearance of ␤-amyloid pathology is paralleled by the recovery of neuronal and cytoskeletal morphology, 20, 21 by the rescue of synaptic electrophysiological functions and neurotransmission, [22] [23] [24] and by signs of neuroprotection, 25 as well as by restored behavioral functions. 2,26 -28 While many antibodies show signs of efficacy in experimental animals, there are also striking differences among different antibodies, both with respect to mechanism of action as well as to potential safety considerations. For example, an antibody against the central domain of A␤ is efficacious in preserving synapses and behavior without clearing ␤-amyloid plaques, 13 an activity consistently demonstrated with other antibodies directed either against the N-terminal or the C-terminal domains. 11, 12, 16, 17 On the other hand, the antibody against the central domain of A␤ did not cause microhemorrhages, and activity observed with antibodies against N-terminal or C-terminal domains. 16, 29, 30 These differences may be related to different mechanisms of action within brain or plasma. To date, at least five, mutually nonexclusive, mechanisms of immunotherapy are discussed. These include clearance of ␤-amyloid by phagocytosis, antibody-mediated shift of the equilibrium toward A␤ monomers favoring clearance and degradation, neutralization of toxic oligomeric A␤ species, peripheral A␤ sink and efflux of soluble A␤ species from brain, and antibody-independent, cell-mediated clearance of ␤-amyloid plaques (for review, see references 10, 31 ).
INITIAL CLINICAL TRIALS
Together, these findings led to initial phase I and phase II clinical trials with aggregated A␤42 and the Th1 response-activating adjuvant QS-21 (Elan/Wyeth AN1792 trial). 32 During the later stages of the phase I trial, the emulsifier polysorbate 80 was added to the active vaccine, a change to the formulation after which the observed immune responses shifted from a predominantly Th2-biased response to a pro-inflammatory Th1 response. 33 Following the formulation change, an initial case with meningoencephalitis and vascular T-lymphocyte infiltrations occurred, 34 and in the subsequent phase II study, 18 further patients, or 6% of the patients treated with the active vaccine, developed forms of subacute aseptic meningoencephalitis after having received mostly two doses, and in some cases one or three of the initially planned six doses of the active vaccine. 35 Besides the T-cell reaction, the active vaccination also led to a humoral immune response in a subpopulation of the vaccinated patients with significantly increased IgG and IgM titers, 36 -38 but antibody titers were unrelated to the occurrence or the severity of meningoencephalitis. 35 There was even an individual case with severe meningoencephalitis, but with no detectable antibody titers indicating that the humoral immune response was not required to cause meningoencephalitis.
Long-term follow-up of the Zurich cohort of actively vaccinated patients revealed increased titers of antibodies reacting with brain ␤-amyloid plaques 36 ; these patients had significantly slower decline of cognitive functions and daily living capacities as compared to the nonresponders. 38 Likewise, immune responders with high antibody titers in the multicenter cohort scored significantly better in composite scores of memory functions as compared with low-responders and nonresponders, or compared with the placebo group of patients. 39 Despite these consistent findings of titer-dependent effects on cognition, overall comparisons of the active vaccine group versus the placebo group failed to show significant differences among groups. 37 This could have been related to the fact that there was little decline in ADAS-cog-related cognitive functions in the placebo group. 37, 40 In the same study, decreased CSF levels of tau protein, an intraneuronal microtubule-associated protein, were found, possibly as a correlate of slowed neuronal degeneration. 37 Histopathological examinations of autopsy tissues obtained from individual patients who died from unrelated causes revealed patchy patterns of ␤-amyloid plaque clearance in association with increased antibody titers, with some regions virtually free of ␤-amyloid plaque pathology. 34, [41] [42] [43] In several cases, reductions in ␤-amyloid plaques were associated with increased brain tissue concentrations of water and detergent-soluble forms of A␤, 44 suggesting biological plaque-clearing activity of antibodies generated as a result of vaccination. No ␤-amyloid clearance was observed in a single case without detectable antibody titers. 44 Together these observations suggest biologically relevant activities of A␤ antibodies on ␤-amyloid plaque pathology in patients with Alzheimer's disease (AD).
SECOND-GENERATION ACTIVE VACCINES
These combined data obtained in the pre-clinical experiments and the observations in the initial clinical active vaccination trials led to the development of a second generation of presumably safer active vaccines with less strong Th1-cell activating formulations and with C-terminally truncated A␤ fragments, as the A␤ C-terminus contains T-cell activating epitopes (Table 1) . Several active vaccination approaches are currently tested in clinical trials (www.clinicaltrials.gov) including the Merck V950 trial, the Novartis/Cytos CAD-106 trial using a virus-like particle-linked N-terminal A␤ peptide fragment, as well as the Affiris Affitope AD01 and AD02 active vaccination trials with A␤ peptide mimetics. The Elan/Wyeth ACC-001 phase II active vaccination trial with an N-terminal A␤ peptide fragment conjugated to a carrier protein was recently suspended because of transient skin lesions in a single patient who participated in the study. Studies to determine the underlying pathophysiology of the transient skin lesions are ongoing (www. clinicaltrials.gov).
HUMANIZED MONOCLONAL ANTIBODIES
The passive transfer of therapeutic antibodies can circumvent unwanted T-cell responses associated with active vaccination, while maintaining important biological activities involved in efficacy. As a consequence, several clinical trials with humanized monoclonal antibodies directed against a large variety of different linear and conformational A␤ epitopes are ongoing. For example, Elan/ Wyeth is testing Bapineuzumab, a humanized monoclonal antibody against the N-terminus of A␤, thereby targeting a wide range of soluble and aggregated forms of A␤ including ␤-amyloid plaques and possibly even N-terminally truncated forms of A␤ assembled within A␤ aggregates. The Bapineuzumab development program is currently entering phase III in large patient cohorts, some of which are stratified according to the ApoE genotype (www.clinicaltrials.gov). In addition, a phase I study testing subcutaneous Bapineuzumab formulations is being pursued (www.clinicaltrials.gov). Ely Lilly (Indianapolis, IN) is testing LY2062430, a humanized monoclonal antibody against the central domain of A␤. This antibody may utilize a different mechanism of action because it does not directly bind to and clear brain ␤-amyloid plaques, but it reverses behavioral deficits and prevents further amyloid build-up in experimental animals, presumably via a peripheral A␤ sink mechanism followed by efflux of soluble forms of A␤. 13 Reported phase I data indicated safety of LY2062430, which is now being tested in a phase II trial (www.clinicaltrials-.gov). Pfizer is testing the Rinat RN-1219/PF-04360365 humanized monoclonal antibody directed against the Cterminal domain of A␤ in a phase I trial. While murine antibodies against a similar C-terminal epitope cleared brain ␤-amyloid deposits and reversed behavioral deficits in transgenic mouse models, they also increased vascular amyloid and microhemorrhage, 16, 17 activities that were effectively prevented by using the de-glycosylated forms of the antibodies. 45 In a phase I study, Hoffmann-La Roche (Basel, Switzerland) is testing the humanized monoclonal antibody R1450 against combined central-and N-terminal domains in several European countries (www.roche-trials.com). R-1450 was selected to cross the blood brain barrier (BBB) to bind to both soluble A␤ and ␤-amyloid deposits with high affinity (Bohrmann et al.,10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy, Hong Kong, 2008). In addition, intravenous IgG preparations containing low concentrations of naturally occurring A␤ antibodies have shown signs of pilot efficacy in a phase II trial, 46 and a phase III trial was recently announced by Baxter BioScience (Deerfield, IL) ( Table 1) . The results will provide important insights into the mechanisms of A␤ immunotherapy, as well as on safety profiles of both active versus passive approaches and different A␤-related epitopes targeted by the different antibodies.
BLOOD-BRAIN BARRIER PASSAGE
With a few exceptions of small antibody fragments, most current approaches of passive antibody transfer rely on intact IgG molecules, but several of the proposed mechanisms of action-phagocytosis, disaggregation, and neutralization-rely on the presence of therapeutically relevant IgG concentrations within the CNS. Antibody transport across the BBB is thus a critical issue for both active and passive A␤ immunotherapy relying on any of the previously mentioned mechanisms. Despite the large molecular mass of IgG, a small fraction can penetrate the BBB by passive diffusion or by leakage. Available data from the initial active vaccination trial suggests that an estimated fraction of 0.1 to 1% of plasma IgG antibodies against ␤-amyloid were present within the CNS, 36, 38 and immunohistological analyses of autopsy tissues obtained from participants of the AN-1792 study indicated the presence of IgG on the remaining ␤-amyloid plaques. 34 Within the CNS, antibodies are stabilized by binding to the high local concentrations of target epitopes in ␤-amyloid fibrils, and the result is very slow off-rates of the IgG-A␤ interaction. As a result, antibodies can accumulate at brain ␤-amyloid deposits, and even small amounts of antibodies penetrating the BBB may be sufficient to cause therapeutically relevant brain concentrations over time. As an alternative, peripheral mechanisms of action as provided by the A␤ sink hypothesis and efflux of A␤ species from brain-and IgMmediated A␤ hydrolysis does not require the presence of antibody within the CNS; 13, 31 for these approaches, antibody-A␤ interactions in plasma are sufficient.
CONGOPHILIC AMYLOID ANGIOPATHY AND MICROHEMORRHAGES
Studies in transgenic mice indicated the possibility of antibody treatment-related microhemorrhages associated with pre-existing congophilic amyloid angiopathy (CAA). 16, 29 These may be related to interactions of A␤ antibodies with the vascular amyloid causing structural fragility of degenerated smooth muscle and endothelial cells, whereas other antibodies that do not act centrally do not cause microhemorrhages. 30 Antibody-mediated increases in microhemorrhages can also be related to Fc effector functions as de-glycosylated IgG without effector functions have a significantly reduced ability to induce microhemorrhages in transgenic mice. 16, 45 Clinical studies will show whether this concern is relevant for safety of A␤ immunotherapy in human patients. In fact, 3 of 22 patients who had received Bapineuzumab in the initial phase I study had transient subclinical MRI signs develop that were consistent with vasogenic edema. 39 On the other hand, A␤ antibodies can also prevent the deposition of vascular amyloid, 47 and they may contribute to vascular repair following clearance of vascular amyloid (Games et al., 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy, Hong Kong, 2008).
A related concern is that CAA could increase as a result of clearance of ␤-amyloid from the neuropil, followed by increased transport of A␤ to the vasculature and accumulation at the blood vessel walls. This concern was raised by severe CAA in initial autopsy findings in patients with AD who received the AN1792 active A␤ vaccination. 34, 41, 42 Likewise, active vaccination of transgenic mice increased vascular amyloid while decreasing parenchymal ␤-amyloid plaque pathology. 19 Such increases in CAA, however, are not observed with all A␤ antibodies, 30 and they were not observed in AN1792 study participants who survived the initial vaccination for a longer time period, suggesting a time-dependent course of initial accumulation of vascular amyloid followed later by clearance.
REDUCTIONS OF BRAIN VOLUME
Morphometric analyses of brain volumes suggested reduced brain volume in actively vaccinated patients as compared with the placebo-treated control group. 48 Although these findings are matter of serious concerns, they do not necessarily reflect accelerated tissue loss and accelerated neurodegeneration. Clearance of large amounts of ␤-amyloid may be associated with volume reductions, and they may be associated with local decreases related to water content, and accompanied by reductions in glial cell volume. Initial long-term observations in individual patients appear to support this hypothesis (Nitsch, 10th International Hong Kong/Springfield Pan-Asian Symposium on Advances in Alzheimer Therapy, Hong Kong, 2008).
NEUROFIBRILLARY TANGLE PATHOLOGY
Besides ␤-amyloid, the neuropathology of AD is characterized by the formation within neurons of neurofibrillary tangles. These consist of abnormally phosphorylated tau proteins that aggregate to form paired helical filaments in the cell bodies and dendrites where they disrupt cytoskeletal functions leading to the degeneration of neurons with the neurofibrillary tangle remaining deposited within the neuropil at the end of this process. Autopsy findings in patients who had participated in the initial active vaccination trial consistently show the persistence of neurofibrillary tangles, in particular also in regions with signs of ␤-amyloid clearance indicating that A␤ immunotherapy is not effective in clearing pre-existing neurofibrillary tangles. 34, 41, 42, 49 On the other hand, because ␤-amyloid or the related toxic aggregation intermediates can trigger the formation of neurofibrillary tangles, 50 -54 therapeutic reduction of ␤-amyloid or its related toxic oligomers may well be effective in preventing the formation of further downstream neurofibrillary tangle pathology, as suggested by data in transgenic mice, in which A␤ antibodies reduced both ␤-amyloid and early, but not late forms of hyperphosphorylated tau. 21 Therefore, A␤ immunotherapy could be active in preventing neurofibrillary tangle formation without affecting numbers or the morphology of pre-existing neurofibrillary tangles.
STRUCTURE OF THE THERAPEUTIC TARGET
Accumulating experimental evidence indicates toxicity of oligomeric assemblies, including A␤*56 55 and yet smaller oligomers including dimers can attain toxic functions (for review, see 56 -58 ). Early intracellular A␤ aggregates associated with impaired neuronal functions and dendritic structures in transgenic mouse models can preceed ␤-amyloid plaque deposition in the neuropil by several months. 23, 59 Neuropathology in autopsy samples shows dystrophic neurites surrounding ␤-amyloid plaques, as well as gradients of neurite pathology, where the degree of pathology decreases with increasing distance from the ␤-amyloid plaque. 60 Local concentration gradients of toxic oligomeric A␤ aggregation intermediates in the immediate surroundings of, and within, ␤-amyloid plaques may explain this finding. The further development of A␤ immunotherapy will focus on approaches that selectively target pathogenic and toxic structures with little or no cross-reactivity with APP derivatives occurring during physiological proteolytic processing.
OUTLOOK
Despite the fact that one of the initial A␤ immunotherapy trials failed because of autoreactive T-cell responses in 6% of the vaccinated patients, optimism regarding the development of A␤ immunotherapy AD prevails. A wealth of information derived from ongoing active vaccination and passive immunotherapy approaches with humanized monoclonal antibodies is foreseeable for the near future. After removal of A␤-mediated toxicity, cognitive rehabilitation and recovery of neuronal functions lost to neurodegeneration will be an important future goal. Likewise, preclinical diagnosis and prevention via surrogate markers, risk factors, and ␤-amyloid imaging 61 will be a future direction in the joint global struggle against dementia.
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